<code id='73BDDBD80D'></code><style id='73BDDBD80D'></style>
    • <acronym id='73BDDBD80D'></acronym>
      <center id='73BDDBD80D'><center id='73BDDBD80D'><tfoot id='73BDDBD80D'></tfoot></center><abbr id='73BDDBD80D'><dir id='73BDDBD80D'><tfoot id='73BDDBD80D'></tfoot><noframes id='73BDDBD80D'>

    • <optgroup id='73BDDBD80D'><strike id='73BDDBD80D'><sup id='73BDDBD80D'></sup></strike><code id='73BDDBD80D'></code></optgroup>
        1. <b id='73BDDBD80D'><label id='73BDDBD80D'><select id='73BDDBD80D'><dt id='73BDDBD80D'><span id='73BDDBD80D'></span></dt></select></label></b><u id='73BDDBD80D'></u>
          <i id='73BDDBD80D'><strike id='73BDDBD80D'><tt id='73BDDBD80D'><pre id='73BDDBD80D'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          knowledge

          author:entertainment    - browse:62433
          Alastair Grant/AP

          LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

          The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met. 

          advertisement

          AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time